MX2024007473A - Activador del linfocito t dirigido al mhc doble. - Google Patents
Activador del linfocito t dirigido al mhc doble.Info
- Publication number
- MX2024007473A MX2024007473A MX2024007473A MX2024007473A MX2024007473A MX 2024007473 A MX2024007473 A MX 2024007473A MX 2024007473 A MX2024007473 A MX 2024007473A MX 2024007473 A MX2024007473 A MX 2024007473A MX 2024007473 A MX2024007473 A MX 2024007473A
- Authority
- MX
- Mexico
- Prior art keywords
- mhc
- targeting
- dual
- lymphocyte activator
- domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163289380P | 2021-12-14 | 2021-12-14 | |
| US202263317256P | 2022-03-07 | 2022-03-07 | |
| US202263328417P | 2022-04-07 | 2022-04-07 | |
| PCT/EP2022/085689 WO2023110918A1 (en) | 2021-12-14 | 2022-12-13 | Dual mhc-targeting t cell engager |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007473A true MX2024007473A (es) | 2024-09-10 |
Family
ID=84887466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007473A MX2024007473A (es) | 2021-12-14 | 2022-12-13 | Activador del linfocito t dirigido al mhc doble. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250002586A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4448570A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024546875A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240116828A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022413444A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3240046A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024007473A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023110918A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025210181A1 (en) * | 2024-04-04 | 2025-10-09 | Cdr-Life Ag | Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| CA2326389C (en) | 1998-04-21 | 2007-01-23 | Micromet Gesellschaft Fur Biomedizinische Forschung Mbh | Novel cd19xcd3 specific polypeptides and uses thereof |
| AU2003264009A1 (en) | 2002-08-15 | 2004-03-03 | Epitomics, Inc. | Humanized rabbit antibodies |
| JP3803790B2 (ja) | 2003-02-17 | 2006-08-02 | 株式会社東北テクノアーチ | 新規なダイアボディ型二重特異性抗体 |
| CN100415765C (zh) | 2003-08-07 | 2008-09-03 | 宜康公司 | 兔单克隆抗体的人源化方法 |
| US8076459B2 (en) | 2003-10-16 | 2011-12-13 | Micromet Ag | Multispecfic deimmunized CD3-binders |
| SG188175A1 (en) | 2004-06-03 | 2013-03-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
| JP4902674B2 (ja) | 2006-03-09 | 2012-03-21 | エフ.ホフマン−ラ ロシュ アーゲー | 抗薬物抗体アッセイ法 |
| CA2673470A1 (en) | 2006-12-21 | 2008-07-03 | Macrogenics, Inc. | Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity |
| NZ579594A (en) | 2007-03-12 | 2012-03-30 | Esbatech Alcon Biomed Res Unit | Sequence based engineering and optimization of single chain antibodies |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| NZ601583A (en) | 2007-05-21 | 2013-08-30 | Bristol Myers Squibb Co | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| NZ581468A (en) | 2007-06-25 | 2012-09-28 | Esbatech Alcon Biomed Res Unit | Methods of modifying antibodies, and modified antibodies with improved functional properties |
| CN101688200B (zh) | 2007-06-25 | 2012-08-08 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 单链抗体的基于序列的改造和优化 |
| PL2307458T3 (pl) | 2008-06-25 | 2018-08-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała |
| PL2307455T3 (pl) | 2008-06-25 | 2017-09-29 | Esbatech, An Alcon Biomedical Research Unit Llc | Optymalizacja rozpuszczalności cząsteczek immunowiążących |
| KR102391731B1 (ko) | 2013-01-14 | 2022-04-27 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| EP3587448B1 (en) | 2013-03-15 | 2021-05-19 | Xencor, Inc. | Heterodimeric proteins |
| HUE050159T2 (hu) | 2013-12-17 | 2020-11-30 | Genentech Inc | Anti-CD3 antitestek és alkalmazási eljárások |
| EP4137816B1 (en) | 2014-02-11 | 2025-03-19 | Genzyme Corporation | Assays for detecting the presence or amount of an anti-drug antibody |
| JP6696982B2 (ja) | 2014-11-26 | 2020-05-20 | ゼンコー・インコーポレイテッドXencor、 Inc. | Cd3および腫瘍抗原に結合するヘテロ二量体抗体 |
| WO2018178307A1 (en) | 2017-03-31 | 2018-10-04 | Ablynx N.V. | Improved immunogenicity assays |
| US20190016802A1 (en) * | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Dual specificity polypeptide molecule |
| KR20200142525A (ko) | 2018-04-05 | 2020-12-22 | 노파르티스 아게 | 암에 대한 삼중특이성 결합 분자 및 이의 용도 |
| KR20220015382A (ko) * | 2019-05-29 | 2022-02-08 | 큐 바이오파마, 인크. | 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법 |
| CA3148161A1 (en) | 2019-09-05 | 2021-03-11 | Adverum Biotechnologies | Anti-drug antibody assay |
| NL2024375B1 (en) * | 2019-12-04 | 2021-08-31 | Apo T B V | Methods and means for attracting immune effector cells to tumor cells. |
| AU2020402581A1 (en) * | 2019-12-11 | 2022-06-23 | Molecular Partners Ag | Designed ankyrin repeat domains with altered surface residues |
| EP4304726A1 (en) | 2021-03-09 | 2024-01-17 | CDR-Life AG | Mage-a4 peptide-mhc antigen binding proteins |
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
-
2022
- 2022-12-13 CA CA3240046A patent/CA3240046A1/en active Pending
- 2022-12-13 KR KR1020247023302A patent/KR20240116828A/ko active Pending
- 2022-12-13 AU AU2022413444A patent/AU2022413444A1/en active Pending
- 2022-12-13 WO PCT/EP2022/085689 patent/WO2023110918A1/en not_active Ceased
- 2022-12-13 JP JP2024535534A patent/JP2024546875A/ja active Pending
- 2022-12-13 MX MX2024007473A patent/MX2024007473A/es unknown
- 2022-12-13 EP EP22839165.2A patent/EP4448570A1/en active Pending
-
2024
- 2024-06-06 US US18/736,330 patent/US20250002586A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024546875A (ja) | 2024-12-26 |
| US20250002586A1 (en) | 2025-01-02 |
| CA3240046A1 (en) | 2023-06-22 |
| KR20240116828A (ko) | 2024-07-30 |
| WO2023110918A1 (en) | 2023-06-22 |
| EP4448570A1 (en) | 2024-10-23 |
| AU2022413444A1 (en) | 2024-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124182T1 (el) | Αντισωματα anti-tmprss2 και θραυσματα δεσμευσης αντιγονου | |
| PE20231201A1 (es) | Tratamiento de combinacion | |
| CL2021001744A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324) | |
| CY1124091T1 (el) | Βελτιωμενο πολυπεπτιδικο μοριο διπλης ειδικοτητας | |
| CL2018002490A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866) | |
| MX2023002374A (es) | Anticuerpo biespecifico anti-calr-cd3 mutante escindido y composicion farmaceutica. | |
| PE20210375A1 (es) | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales | |
| CL2023000657A1 (es) | Péptido que se une al mhc | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| AU2018449846A8 (en) | An anti-B7-H3 antibody | |
| PE20191661A1 (es) | Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos | |
| EA202190542A1 (ru) | Сконструированные биспецифические белки | |
| BR112019008861A2 (pt) | anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3) | |
| CL2017000250A1 (es) | Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso | |
| PE20141658A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| MX2020013606A (es) | Constructos de anticuerpos multiespecificos. | |
| MX2022014852A (es) | Métodos para tratar o prevenir infecciones por sars-cov-2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2. | |
| CL2019002953A1 (es) | Anticuerpo anti-pd-l1 y uso del mismo. | |
| BR112023003366A2 (pt) | Moléculas multiespecíficas de ligação ao antígeno que têm como alvo hiv e métodos de uso | |
| CU20230010A7 (es) | Neoantígenos ras | |
| CY1118420T1 (el) | Αντι-ιδιοτυπικο αντισωμα εναντι ενος αντισωματος εναντι του βητα αμυλοειδους πεπτιδιου | |
| CL2023000658A1 (es) | Péptido que se une al mhc | |
| MX2023009715A (es) | Anticuerpo de dominio individual biespecífico contra el ligando de muerte programada (pd-l1) y el cúmulo de diferenciación 47 (cd47) y uso del mismo. | |
| MX2020010653A (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso. | |
| BR112021026309A2 (pt) | Anticorpos para ativação de células t |